Switch On Your HIV Smarts.

Webinar: PrEP and Women’s HIV Risk

, by San Francisco AIDS Foundation

BluePillsCROPPrEP, short for pre-exposure prophylaxis, is a relatively new HIV prevention tool in which HIV-negative people take a daily pill to help reduce their risk of infection. It’s an exciting new option—but like any HIV risk-reduction intervention, people can only use it and benefit from it if they recognize they are at risk in the first place.

The Centers for Disease Control and Prevention’s interim guidance on Truvada PrEP use by heterosexual adults explains that daily PrEP can be a safe and effective option for “women and men at very high risk for acquiring HIV from penile-vaginal sex” and to protect the HIV-negative partner when a serodiscordant couple is trying to conceive.

But what does “very high risk” mean to women in different contexts? How do women perceive and understand their own risk for acquiring HIV? And how does their perception of HIV risk affect their interest (or lack of interest) in PrEP and their potential to seek information about it, talk with their clinicians about it, and use it effectively?

These are questions the U.S. Women and PrEP Working Group is exploring in communities across the country. Join the conversation! Sign up for the working group’s December 9 webinar, “Risky Women: Disrupting Simple Notions of Women’s HIV Risk,” to ask questions and share perspectives of your own. See the excerpted webinar invitation below, and register online.

Risky Women: Disrupting Simple Notions of Women’s HIV Risk

  • Date: Mon, Dec 9, 2013
  • Time: 11:00 AM EST
  • Duration: 1 hour 30 minutes

In 2012, the FDA approved Truvada for PrEP use among adult women and men who are “at risk” of HIV infection in the U.S. But exactly which women are at risk, how such risk is defined and understood, and whether or not women see themselves in this way is not entirely clear. Speakers in this webinar will present what is known from social and behavioral science and community experience about the definitions and perceptions of HIV risk among women that are relevant to their potential PrEP use.

Presentations will be followed by discussion and a question and answer period. The webinar is co-sponsored by AVAC, the HIV Prevention Justice Project, the National Women’s Health Network, SisterLove, Inc. and the Well Project.


Vignetta Charles, PhD, Senior Vice President, AIDS United


Judith Auerbach, PhD, Adjunct Professor, Center for AIDS Prevention Studies, University of California, San Francisco; and Consultant to AIDS United and San Francisco AIDS Foundation

Rivet Amico, PhD, Research Scientist, Center for Health Intervention and Prevention, University of Connecticut

JoAnne Keatley, MSW, Director, Center of Excellence for Transgender Health, University of California, San Francisco

Click here to register for the December 9 webinar.


Comments are closed.